2009 Proxy Materials

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Enzon Pharmaceuticals Inc.s financial performance into perspective.

Print Print   Email Email

2009 Proxy Materials

PDF    2008 Annual Report 1.6 MB
PDF    2009 Proxy Statement 353.9 KB
PDF    2009 Proxy Card 29.0 KB


Hide / ShowView Archived Reports

If you are not a shareowner - you may request printed copies here: Investor Kit

Search
(ENZN) NASDAQ
Last Trade 10.310
Change(%) price 0.46
Volume 1,303,400
Mar 10, 2010 4:00 PM ET

Sign up to receive Enzon Pharmaceuticals Inc. financial information by email.

click here to sign up

News

  • Details on upcoming events are not yet available.
    click here to be notified of all upcoming events.

  • subscribe to our news feed


    Really Simple Syndication is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.

  • 03-08-2010

    Enzon's Debt is Reduced by $116 Million

    ­ ­ --Debt converted into an additional 13.5 million shares--
    ­ ­

    click here for more information

  • 02-24-2010

    Enzon Opens Pediatric Study of PEG-SN38

    ­ ­ ­ ­

    click here for more information

  • 02-22-2010

    Enzon Board of Directors Appoints Executive Committee

    ­ ­ Jeffrey Buchalter Steps Down as CEO of Enzon
    ­ ­

    click here for more information

  • 02-17-2010

    Enzon Reports 2009 Results

    ­ ­ --Sale of Specialty Pharmaceutical Business brings over $300 million in value--
    ­ ­

    click here for more information